Header Logo

Connection

Jeffrey Kordower to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Jeffrey Kordower has written about Parkinson Disease.
Jeffrey Kordower
Connection Strength
20.198
Parkinson Disease
  1. Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
    View in: PubMed
    Score: 0.489
  2. Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handb Clin Neurol. 2023; 192:57-71.
    View in: PubMed
    Score: 0.469
  3. The Unbearable Lightness of Brundin. J Parkinsons Dis. 2022; 12(4):1069-1072.
    View in: PubMed
    Score: 0.438
  4. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
    View in: PubMed
    Score: 0.413
  5. Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy". Mov Disord. 2020 11; 35(11):2120-2121.
    View in: PubMed
    Score: 0.404
  6. Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in?vivo. Stem Cells Transl Med. 2021 02; 10(2):278-290.
    View in: PubMed
    Score: 0.401
  7. Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease. Mov Disord. 2020 08; 35(8):1312-1314.
    View in: PubMed
    Score: 0.395
  8. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
    View in: PubMed
    Score: 0.385
  9. Immunotherapy in Parkinson's disease: Current status and future directions. Neurobiol Dis. 2019 12; 132:104587.
    View in: PubMed
    Score: 0.372
  10. Spreading of alpha-synuclein - relevant or epiphenomenon? J Neurochem. 2019 09; 150(5):605-611.
    View in: PubMed
    Score: 0.369
  11. Temporal evolution of microglia and a-synuclein accumulation following foetal grafting in Parkinson's disease. Brain. 2019 06 01; 142(6):1690-1700.
    View in: PubMed
    Score: 0.366
  12. Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease. Mov Disord. 2019 09; 34(9):1274-1278.
    View in: PubMed
    Score: 0.366
  13. Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier? Mov Disord. 2019 09; 34(9):1279-1282.
    View in: PubMed
    Score: 0.361
  14. Disease Modification for Parkinson's Disease: Axonal Regeneration and Trophic Factors. Mov Disord. 2018 05; 33(5):678-683.
    View in: PubMed
    Score: 0.337
  15. Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol. 2018 03; 83(3):562-574.
    View in: PubMed
    Score: 0.336
  16. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 12; 298(Pt B):225-235.
    View in: PubMed
    Score: 0.326
  17. Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In?Vivo. Stem Cell Reports. 2017 07 11; 9(1):149-161.
    View in: PubMed
    Score: 0.319
  18. Aging and Parkinson's disease: Different sides of the same coin? Mov Disord. 2017 Jul; 32(7):983-990.
    View in: PubMed
    Score: 0.318
  19. a-Synuclein nonhuman primate models of Parkinson's disease. J Neural Transm (Vienna). 2018 03; 125(3):385-400.
    View in: PubMed
    Score: 0.316
  20. What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias. Mov Disord. 2017 04; 32(4):483-484.
    View in: PubMed
    Score: 0.315
  21. Targeting a-Synuclein as a therapy for Parkinson's disease: The battle begins. Mov Disord. 2017 02; 32(2):203-207.
    View in: PubMed
    Score: 0.311
  22. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.310
  23. How strong is the evidence that Parkinson's disease is a prion disorder? Curr Opin Neurol. 2016 Aug; 29(4):459-66.
    View in: PubMed
    Score: 0.301
  24. Fetal grafts for Parkinson's disease: Decades in the making. Proc Natl Acad Sci U S A. 2016 Jun 07; 113(23):6332-4.
    View in: PubMed
    Score: 0.297
  25. AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Methods Mol Biol. 2016; 1382:485-90.
    View in: PubMed
    Score: 0.289
  26. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.289
  27. Trophic factors for Parkinson's disease: To live or let die. Mov Disord. 2015 Nov; 30(13):1715-24.
    View in: PubMed
    Score: 0.285
  28. Parkinson's disease and prion disease: Straining the comparison. Mov Disord. 2015 Nov; 30(13):1727.
    View in: PubMed
    Score: 0.285
  29. The prion hypothesis of Parkinson's disease. Curr Neurol Neurosci Rep. 2015 May; 15(5):28.
    View in: PubMed
    Score: 0.276
  30. Gene therapy for Parkinson's disease: still a hot topic? Neuropsychopharmacology. 2015 Jan; 40(1):255-6.
    View in: PubMed
    Score: 0.269
  31. Peripheral alpha-synuclein and Parkinson's disease. Mov Disord. 2014 Jul; 29(8):963-6.
    View in: PubMed
    Score: 0.260
  32. The prion hypothesis of Parkinson's disease: this hot topic just got hotter. Mov Disord. 2014 Jul; 29(8):988.
    View in: PubMed
    Score: 0.259
  33. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
    View in: PubMed
    Score: 0.258
  34. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord. 2014 Jul; 29(8):999-1009.
    View in: PubMed
    Score: 0.249
  35. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
    View in: PubMed
    Score: 0.244
  36. Trophic factor gene therapy for Parkinson's disease. Mov Disord. 2013 Jan; 28(1):96-109.
    View in: PubMed
    Score: 0.235
  37. Cell therapy for Parkinson's disease: what next? Mov Disord. 2013 Jan; 28(1):110-5.
    View in: PubMed
    Score: 0.235
  38. Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts. J Parkinsons Dis. 2013; 3(4):581-91.
    View in: PubMed
    Score: 0.235
  39. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 2012 May; 27(6):716-9.
    View in: PubMed
    Score: 0.224
  40. Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy. Prog Brain Res. 2012; 200:221-41.
    View in: PubMed
    Score: 0.219
  41. GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol Disord Drug Targets. 2011 Sep 01; 10(6):703-11.
    View in: PubMed
    Score: 0.214
  42. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2012 May; 27(6):709-15.
    View in: PubMed
    Score: 0.212
  43. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci. 2011 06; 12(6):359-66.
    View in: PubMed
    Score: 0.210
  44. Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J Med. 2011 Jan-Feb; 78(1):126-58.
    View in: PubMed
    Score: 0.204
  45. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
    View in: PubMed
    Score: 0.203
  46. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.200
  47. Gene therapy for Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S161-73.
    View in: PubMed
    Score: 0.191
  48. Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010; 184:237-64.
    View in: PubMed
    Score: 0.191
  49. Are growth factors the answer? Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S176-80.
    View in: PubMed
    Score: 0.189
  50. Modeling Parkinson's disease. Ann Neurol. 2009 Oct; 66(4):432-6.
    View in: PubMed
    Score: 0.187
  51. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.183
  52. Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another? Neuropsychopharmacology. 2009 Jan; 34(1):254.
    View in: PubMed
    Score: 0.178
  53. Trophic factors therapy in Parkinson's disease. Prog Brain Res. 2009; 175:201-16.
    View in: PubMed
    Score: 0.178
  54. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008 Dec 15; 23(16):2303-6.
    View in: PubMed
    Score: 0.177
  55. Future of cell and gene therapies for Parkinson's disease. Ann Neurol. 2008 Dec; 64 Suppl 2:S122-38.
    View in: PubMed
    Score: 0.177
  56. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May; 14(5):504-6.
    View in: PubMed
    Score: 0.169
  57. Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Exp Neurol. 2008 Jan; 209(1):34-40.
    View in: PubMed
    Score: 0.162
  58. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov Disord. 2007 Aug 15; 22(11):1630-3.
    View in: PubMed
    Score: 0.162
  59. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord. 2007 Jun 15; 22(8):1124-32.
    View in: PubMed
    Score: 0.160
  60. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
    View in: PubMed
    Score: 0.153
  61. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S89-103.
    View in: PubMed
    Score: 0.148
  62. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.145
  63. Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 2006; 15(3):251-65.
    View in: PubMed
    Score: 0.144
  64. Proximity proteomics reveals unique and shared pathological features between multiple system atrophy and Parkinson's disease. Acta Neuropathol Commun. 2025 Mar 23; 13(1):65.
    View in: PubMed
    Score: 0.137
  65. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S120-32; discussion S132-4.
    View in: PubMed
    Score: 0.117
  66. Etiology of Parkinson's disease: Genetics and environment revisited. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):13972-4.
    View in: PubMed
    Score: 0.116
  67. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
    View in: PubMed
    Score: 0.114
  68. Stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau in cellular and mouse models of tauopathies. Autophagy. 2023 02; 19(2):660-677.
    View in: PubMed
    Score: 0.114
  69. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002 Jun 15; 22(12):4942-54.
    View in: PubMed
    Score: 0.113
  70. In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proc Natl Acad Sci U S A. 2022 02 01; 119(5).
    View in: PubMed
    Score: 0.110
  71. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog Brain Res. 2002; 138:421-32.
    View in: PubMed
    Score: 0.109
  72. Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
    View in: PubMed
    Score: 0.099
  73. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. 2020 03 17; 94(11):481-494.
    View in: PubMed
    Score: 0.096
  74. Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson's Disease? J Parkinsons Dis. 2020; 10(2):405-411.
    View in: PubMed
    Score: 0.095
  75. GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020; 10(3):875-891.
    View in: PubMed
    Score: 0.095
  76. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease. Neurobiol Dis. 2020 02; 135:104352.
    View in: PubMed
    Score: 0.089
  77. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut. 2019 05; 68(5):829-843.
    View in: PubMed
    Score: 0.089
  78. Analysis of age-related changes in psychosine metabolism in the human brain. PLoS One. 2018; 13(2):e0193438.
    View in: PubMed
    Score: 0.084
  79. Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease. Mov Disord. 2018 04; 33(4):652-654.
    View in: PubMed
    Score: 0.083
  80. Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease. Brain. 2017 Nov 01; 140(11):2982-2992.
    View in: PubMed
    Score: 0.082
  81. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep; 32(9):1264-1310.
    View in: PubMed
    Score: 0.081
  82. The Search for a Peripheral Biopsy Indicator of a-Synuclein Pathology for Parkinson Disease. J Neuropathol Exp Neurol. 2017 01 01; 76(1):2-15.
    View in: PubMed
    Score: 0.077
  83. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Transl Med. 2016 12 07; 8(368):368ra174.
    View in: PubMed
    Score: 0.077
  84. Is Axonal Degeneration a Key Early Event in Parkinson's Disease? J Parkinsons Dis. 2016 10 19; 6(4):703-707.
    View in: PubMed
    Score: 0.076
  85. Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. J Parkinsons Dis. 2016 10 19; 6(4):761-770.
    View in: PubMed
    Score: 0.076
  86. Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol Commun. 2016 Apr 04; 4:35.
    View in: PubMed
    Score: 0.074
  87. Preface. Mov Disord. 2016 Feb; 31(2):151.
    View in: PubMed
    Score: 0.073
  88. PGC-1a Promoter Methylation in Parkinson's Disease. PLoS One. 2015; 10(8):e0134087.
    View in: PubMed
    Score: 0.070
  89. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.069
  90. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep. 2013; 3:2157.
    View in: PubMed
    Score: 0.059
  91. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011; 6(12):e28032.
    View in: PubMed
    Score: 0.054
  92. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011 Nov 06; 480(7378):547-51.
    View in: PubMed
    Score: 0.054
  93. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011 Oct; 44(1):38-52.
    View in: PubMed
    Score: 0.053
  94. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
    View in: PubMed
    Score: 0.050
  95. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010 Jun; 16(6):653-61.
    View in: PubMed
    Score: 0.049
  96. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol. 2009 Nov; 66(5):591-6.
    View in: PubMed
    Score: 0.047
  97. Propagation of host disease to grafted neurons: accumulating evidence. Exp Neurol. 2009 Dec; 220(2):224-5.
    View in: PubMed
    Score: 0.047
  98. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther. 2010 Mar; 18(3):579-87.
    View in: PubMed
    Score: 0.047
  99. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 2009 Apr; 64(4):602-12; discussion 612-3.
    View in: PubMed
    Score: 0.045
  100. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.045
  101. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2007 Nov 20; 104(47):18754-9.
    View in: PubMed
    Score: 0.041
  102. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007 May 25; 1147:77-88.
    View in: PubMed
    Score: 0.039
  103. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S469-77.
    View in: PubMed
    Score: 0.039
  104. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis. 2006 Jan; 21(1):165-80.
    View in: PubMed
    Score: 0.035
  105. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003 Sep; 4(9):727-38.
    View in: PubMed
    Score: 0.031
  106. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.031
  107. T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathol. 2020 05; 139(5):855-874.
    View in: PubMed
    Score: 0.024
  108. Loss of One Engrailed1 Allele Enhances Induced a-Synucleinopathy. J Parkinsons Dis. 2019; 9(2):315-326.
    View in: PubMed
    Score: 0.022
  109. Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol. 2006 Jan; 59(1):166-73.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.